Atea Pharmaceuticals, Inc. · NASDAQ:AVIR
Atea Pharmaceuticals — Q1 2021 Earnings Presentation
17 slides from Atea Pharmaceuticals's earnings presentation, May 13, 2021
Slide 1: First Quarter 2021 Financial Results and Corporate Update
First Quarter 2021 Financial Results and Corporate Update May 13, 2021 June 2020
Slide 2: Disclaimers
DISCLAIMERS Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our curr
Slide 3: 1Q 2021 Summary of Scientific Publications and Presentations
1Q 2021 Summary of Scientific Publications and Presentations AT-527 Scientific Highlights: üAT-527 manuscript published in Antimicrobial Agents and Chemotherapy (AAC) highlighting potent in vitro activity against SARS-CoV-2 and other corona viruses üAT-527 Phase 1 results presented in Scientific Spo
Slide 4: Clinical Development Update
AT-527 Clinical Development Update 4
Slide 5: Potential for Impact on Current COVID-19 and Future SARS-CoV Outbreaks
AT-527 Potential for Impact on Current COVID-19 and Future SARS-CoV Outbreaks/Pandemics Prevent/shorten Reduce virus transmission, Oral DAA treatment Accelerate time to hospitalization long-term sequelae clinical recovery profile for COVID-19 Reduce medically • Hospitalized and outpatients attended
Slide 6: Multiple Clinical Trials Active & Reporting Results in 2021 and 2022
AT-527 Multiple Clinical Trials Active & Reporting Results in 2021 and 2022 TRIAL DESCRIPTION TIMING Phase 1 PK safety study, clinical pharmacology and standard drug- Positive results announced with Healthy Volunteers drug interaction trials first cohort; Ongoing Phase 2 Safety and tolerability with
Slide 7: Phase 2 Trial in Hospitalized Patients with Moderate COVID-19
AT-527 Phase 2 Trial in Hospitalized Patients with Moderate COVID-19 Inclusion Criteria: adult patients (≥ 18 years AT-527 Dose 550 mg BID (n=95) old) with risk factors (obesity, diabetes, 2Q / 21 hypertension), symptoms for ≤ 5 days Randomization Interim Placebo BID (n=95) Virology Data Countries:
Slide 8: Phase 2 Outpatient Study in Mild to Moderate Patients +/- Risk Factors
AT-527 AT-527 Phase 2 Outpatient Study in Mild to Moderate Patients +/- Risk Factors Inclusion Criteria: > 18 yrs old, SARS-CoV-2 Multiple Cohorts AT-527 positive 72 hrs prior to randomization, 2Q / 21 mild-to-moderate COVID-19 patients in Randomization Interim Placebo Virology Data outpatient setti
Slide 9: Global Phase 3 Trial in Outpatient Setting in Mild to Moderate Patients
AT-527 Global Phase 3 Trial* in Outpatient Setting in Mild to Moderate Patients +/- Risk Factors AT-527 550 mg BID (n=~950) 2H / 21 Inclusion Criteria: Patients eligible for Anticipated management in an outpatient setting Randomization Results Placebo BID (n~=450) 2:1 Double-blind oral administratio
Slide 10: AT-752 Clinical Proof-of-Concept Program for Dengue Fever
AT-752 Clinical Proof-of-Concept Program for Dengue Fever 10
Slide 11: Phase 1a and Phase 1b Clinical Studies for the Treatment of Dengue Fever
AT-752 Phase 1a and Phase 1b Clinical Studies* for the Treatment of Dengue Fever Inclusion Criteria: healthy volunteers, sequential AT-752 Dose SAD dose-escalation Country: Australia AT-752 Dose MAD Objectives: Safety and PK (with embedded food effect) 1Q / 21 • CTA filed December 2020 Randomization
Slide 12: Financial Summary and Closing Remarks
Financial Summary and Closing Remarks 12
Slide 13: Financial Update
Financial Update Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (in thousands, except share and per share amounts) (Unaudited) Three Months Ended March 31, 2021 2020 Collaboration revenue $ 65,985 $ — Operating expenses Research and development 26,571 2,821 General a
Slide 14: Financial Update: Selected Consolidated Balance Sheet Data
Financial Update Selected Consolidated Balance Sheet Data (in thousands) March 31, December 31, 2021 2020 Assets Cash and cash equivalents $ 833,751 $ 850,117 Working capital “ $ 585,867 $ 547,682 Total assets $ 840,649 $ 863,632 Deferred revenue $ 235,382 $ 301,367 Total stockholders’ equity $ 586,
Slide 15: Atea's Platform Has Generated a Deep Antiviral Pipeline
Atea’s Platform Has Generated a Deep Antiviral Pipeline ssRNA VIRUS THERAPEUTIC INDICATION DISCOVERY PHASE 1 PHASE 2 PHASE 3 HIGHLIGHTS Coronaviridae COVID-19 AT-5271 • AT-527 efficacy results ex-US 2021-2022 Flaviviridae Dengue AT-7522 • Projected near-term launch of AT-527, an oral AT-7873 DAA for
Slide 16: Q & A Session
Q & A Session 16
Slide 17: June 2020
125 Summer Street Boston MA USA 02110 857 284 8891 www.ateapharma.com June 2020 Copyright 2020 Atea Pharmaceuticals